Funding Wizard

The purpose of this initiative is to facilitate genomic research and to disseminate its products to the broader biomedical research community. NHGRI supports both new and existing genomic resources of demonstrated broad value to the research community. Awards under this FOA will support the development and distribution of genomic resources that will be valuable for both basic and clinical genomics research. Such resources include, but are not limited to, those that support: Genomic informatics toolsets, such as biomedical ontologies and analysis toolsets. Comprehensive identification and collections of genomic features, such as functional genomic elements and genetic assay results. Genomic community building efforts, such as standards development. Sample repositories for genomic studies, such as cell line repositories for high-value samples.

The purpose of this funding opportunity announcement (FOA) is to provide investigators with access to resources provided by the Data Management Coordinating Center for Diagnostic Centers of Excellence (RFA-NS-22-051), as part of the next phase of the Undiagnosed Diseases Network. Resources include infrastructure, data management, and clinical research support for a new Network of clinical sites that provide diagnostic services for patients with undiagnosed diseases.

Reissue of RFA-NS-18-020: Understanding the dynamic activity of brain circuits is central to the NIH BRAIN Initiative. This FOA seeks applications for proof-of-concept testing and development of new technologies and novel approaches for recording and modulation (including various modalities for stimulation/activation, inhibition and manipulation) of cells (i.e., neuronal and non-neuronal) and networks to enable transformative understanding of dynamic signaling in the central nervous system (CNS). This FOA seeks exceptionally creative approaches to address major challenges associated with recording and modulating CNS activity, at or near cellular resolution, at multiple spatial and/or temporal scales, in any region and throughout the entire depth of the brain. It is expected that the proposed research may be high-risk, but if successful, could profoundly change the course of neuroscience research. Proposed technologies should be compatible with experiments in behaving animals, validated under in vivo experimental conditions, and capable of reducing major barriers to conducting neurobiological experiments and making new discoveries about the CNS. Technologies may engage diverse types of signaling beyond neuronal electrical activity such as optical, magnetic, acoustic and/or genetic recording/manipulation. Applications that seek to integrate multiple approaches are encouraged. If suitable, applications are expected to integrate appropriate domains of expertise, including biological, chemical and physical sciences, engineering, computational modeling and statistical analysis.

The Federal Transit Administration (FTA) announces the opportunity to apply for $38 million in competitive grants under the Fiscal Year (FY) 2021 Passenger Ferry Grant Program (Ferry Program) (Federal Assistance Listing #20.507). Of that amount, $4 million is available only for low or zero-emission ferries or ferries using electric battery or fuel cell components and the infrastructure to support such ferries. As required by Federal public transportation law, funds will be awarded competitively to designated recipients or eligible direct recipients of Urbanized Area Formula funds to support capital projects to improve existing passenger ferry service, establish new ferry service, and repair and modernize ferry boats, terminals, and related facilities and equipment.

This notice announces a funding opportunity and requests grant applications for FHWA’s National Scenic Byways Program (NSBP) as provided by the Department of Transportation Appropriations Act, 2021 (Public Law 116-260) and the Consolidated Appropriations Act, 2022. Established in Title 23, Section 162 of the United States Code (U.S.C.), the NSBP is a grass-roots collaborative effort to help recognize, preserve, and enhance selected roads throughout the United States. Per 23 U.S.C. 162(b), grants and technical assistance are available to State departments of transportation (State DOT) or Indian Tribes to implement eligible projects on highways designated as National Scenic Byways, All-American Roads (collectively America's Byways®), State scenic byways, or Indian Tribe scenic byways; and plan, design, and develop a State or Indian Tribe scenic byway program. This grant opportunity will result in the distribution of up to $22 million that are currently available. If additional funding is provided for the NSBP during FY 2022, FHWA intends to use those funds for projects selected to receive a grant under this NOFO. This notice identifies selection criteria, application requirements, and technical assistance during the grant solicitation period for this one-time solicitation. The FHWA will distribute these funds, as described in this notice, on a competitive basis in a manner consistent with the selection criteria. For the 2022 NSBP grants, FHWA seeks projects that meet the statutory eligibility and advance one or more of the four goals: (1) Safety; (2) Equity and Accessibility; (3) Economic Strength; and (4) Climate and Sustainability.

The National Institute on Drug Abuse (NIDA) supports a program of longitudinal cohorts to address emerging and high priority research on HIV/AIDS in the context of injection and non-injection substance abuse. These cohorts provide a strong resource platform for current and future collaborative efforts with other investigators to address emerging questions related to HIV pathogenesis, prevention, and treatment in the context of substance abuse, as well as to foster the creativity and efficiency of investigatorinitiated research projects. The diverse research activities among these cohorts include basic immunologic, and virologic studies, as well as studies on HIV prevention and treatment, and the co-morbidities and co-infections associated with HIV and substance abuse. NIDA has determined that a coordinating center (CC) is needed in order to take advantage of these rich sources of data and bio-specimens and optimize collaborations among both the cohort investigators and other researchers not funded under the cohort program. In addition, the CC is expected to establish a virtual repository, and facilitate the leadership of the cohorts steering committee (SC), consisting of representatives from the NIDA-funded cohorts and NIDA staff.

THE PURPOSE OF THIS FOA IS TO SUPPORT RESEARCH THAT ACCELERATES THE DISCOVERY AND DEVELOPMENT OF SAFE AND EFFECTIVE THERAPEUTICS FOR OUD IN PATIENTS WITH CO-OCCURRING COMD. THE THERAPEUTIC INTERVENTIONS MAY INCLUDE MEDICATIONS, DEVICES, OR DIGITAL THERAPEUTICS. THE GOAL IS TO SUPPORT RESEARCH THAT ADDRESSES THE URGENT NEED TO HAVE SAFE AND EFFECTIVE THERAPEUTICS FOR OUD IN PATIENTS WITH CO-OCCURRING COMD.

This funding opportunity announcement (FOA) invites applications to renew current ECHO Cohort Study Sites to extend the capacity of the ECHO Cohort to further investigate the roles of a broad range of early exposures from society to biology on ECHOs five key child health outcome areaspre-, peri- and postnatal, upper and lower airways, obesity, neurodevelopment, and positive healthamong diverse populations. The objectives of this FOA are to solicit applications to 1) lead collaborative ECHO Cohort science, 2) follow up existing ECHO Cohort participants, and 3) implement the ECHO Cohort Data and Biospecimen Collection Protocol using the ECHO Cohort consortiums central data capture system, e.g., REDCap Central. This FOA does not support site-specific analyses and science. Only current ECHO Cohort awardees are eligible to apply. This new funding period will be 7 years in duration provided successful performance in the UG3 phase and the UH3 phase. This FOA runs in parallel with companion FOAs that solicit applications for Cohort Study Sites for a limited competition of follow-up of existing ECHO Cohort participants AND of recruitment of new pregnant participants, their resulting offspring, and, if available, the conceiving partner (RFA ZZZZ), for ECHO Cohort Study Sites only for an open competition of recruitment of new pregnant participants, their resulting offspring, and, if available, the conceiving partner (RFA YYYY), for an ECHO Coordinating Center (RFANNNN), for an ECHO Data Analysis Center (RFA NNNN), for an ECHO Measurement Core (RFA NNNN), and for an ECHO Laboratory Core (RFA NNNN).

The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods, and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical, or translational science.

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (RFA-CA-22-035). This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena